Jennifer Amengual, MD, Appointed New Co-leader of HICCC’s Cancer Genomics and Epigenomics Program
Jennifer Amengual, MD, an innovator in the field of targeted lymphoma therapies, has been named a new co-leader of the Cancer Genomics and Epigenomics (CGE) program at the Herbert Irving Comprehensive Cancer Center (HICCC). She joins Chao Lu, PhD, and Raul Rabadan, PhD, as co-leaders of the CGE program. As she steps into her leadership role at CGE, Amengual discusses the latest research from her lab, recent clinical trials, and her vision for the future of the CGE program.
The Amengual Lab
As a physician-scientist, Amengual’s work focuses on turning research in the lab into personalized treatment platforms. Targeting molecular networks that regulate gene activity, or epigenetic pathways, in B-cell and T-cell lymphomas, is at the forefront of her research.
By investigating epigenetic pathways, the Amengual Lab seeks to alter these diseases at their genetic root – treating the disease before it starts -- instead of managing symptoms.
Specifically, Amengual and her team focus on both epigenetic targeting and novel ways to enhance immunotherapies – via both immune checkpoint inhibitors and bispecific antibodies in the context of lymphoma.
"We have a pretty small lab, but we are pretty successful despite that," says Amengual. "We're like a lean machine."
Recently, with colleagues including Seda Tolu, MD, the lab developed lymphoma organoids to test the efficacy of combining Ruxolitinib JAK-STAT inhibitor with pembrolizumab, an immune checkpoint inhibitor. In this study, they found that when organoids are primed with Ruxolitinib, it allows for better activation of the immune checkpoint inhibitor — blocking signals and reactivating the T-cells to attack the tumor.
The lab launched a clinical trial to further study the collaboration between these two inhibitors in patients.
"We're excited to be performing some correlative studies looking at changes in the tumor microenvironment before and after exposure to these dual therapies," says Amengual.
With her clinical expertise in lymphoma and HIV- and EBV-related hematologic illnesses, Amengual is a PI on a number of clinical trials, enabling patients to access the best opportunities for the treatment of their disease. She is actively involved in the NCI’s National Clinical Trial Network, SWOG, as the Vice-Chair of the Lymphoma Working Group Committee.
“We've been really fortunate to be able to translate a number of our projects that we've had ongoing in the laboratory to clinical trials,” she says. “It's been fantastic to see patients benefit from some of the discoveries we've made in the lab."
A Vision for CGE
The CGE program at the HICCC brings together researchers who study how cancer arises from DNA mutations and epigenetic changes. Program members explore how these two facets of oncology can influence genome integrity in normal cells and create genome instability in cancer cells.
Throughout her tenure as new co-leader of the CGE program, Amengual hopes to work with fellow co-leaders to highlight the important work being done by all its members.
"One of the purposes of our CGE meetings is to stimulate conversation between scientists and clinicians to foster collaborative research,” says Amengual.
To encourage these connections, Amengual hopes to organize program meetings around shared research interests, bringing together members working with similar technologies, investigating related biological processes, or studying common cancer types. By creating opportunities for researchers across disciplines to exchange ideas and approaches, she hopes to spark collaborations that might not otherwise take shape.